Posts Tagged: commercialization in Canada

MaRS Innovation statement on the 2015 Federal Budget

TORONTO, ON (April 23, 2014) — MaRS Innovation congratulates the Federal Government’s deepened commitment to support Canadian research and innovation, particularly in the healthcare sector. In particular, the $42 million over five years dedicated to support the Canadian Centre for Aging and Brain Health Innovation at Baycrest Health Sciences, which includes $32 million in support from the Federal Economic Development Agency for Southern Ontario (FedDev). Baycrest is a founding member institution of MaRS Innovation. “As a Baycrest partner and long-time champions of the ... Read more

Triphase Accelerator announces new cancer collaboration with Sunnybrook Research Institute

TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor. Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR ... Read more

SciBX covers Encycle’s partnership with IRICoR, MaRS Innovation and Merck

"The first disclosed grant under Merck & Co. Inc.'s Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin [a4b7,] inhibitors for inflammatory bowel disease," writes Michael J. Haas in SciBX's feature on the partnership, "Merck Encycles through Canada." The article appears in the publication's December 4, 2014 issue. Read the Encycle press release that prompted this article. The article explores the current grant partnership between Merck, Encycle Therapeutics, MaRS Innovation, the Institute for ... Read more

UTEST gets a mention in TechVibes piece on Canada’s growing start-up scene

TechVibes gave UTEST, an incubator program jointly run by MaRS Innovation and the University of Toronto, a mention in Laura Leslie's "Canada’s Startup Communities Shining Brighter Than the California Sun," published November 24, 2014, which explores the ecosystem-wide supports in place to encourage entrepreneurship in Canada. Leslie writes: Silicon Valley may be the first place that comes to mind when you think of tech startups, but when considering resources, financial support, and a welcoming atmosphere, Canada has been steadily putting itself on the map. ... Read more

MaRS Innovation joins new financing round for AvidBiologics Inc.

TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC). Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company's founding investors. This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity. Today's financing builds on prior ... Read more

Tech Transfer Central features MaRS Innovation’s partnership with St. Michael’s Hospital

Tech Transfer Tactics, the monthly newsletter for Tech Transfer Central.com, has published a feature highlighting MaRS Innovation's Technology Transfer & Scouting (MITTS) services to St. Michael's Hospital. The interview explores the increase in disclosures and commercial activity achieved after MaRS Innovation began offering technology transfer services to the hospital, and was triggered by a July profile published on MaRS Innovation's website describing the collaborative working relationship between the two organizations. The interview includes conversations with Sahail Shariff, commercialization manager in the MITTS division, ... Read more

Xagenic’s Shana Kelley named to Globe and Mail’s Top 12 Canadian Innovators

Dr. Shana Kelley, co-founder of Xagenic Inc. and a professor of biochemistry at the University of Toronto, has been named to the Globe and Mail's Top 12 Canadian Innovators list. The contest solicited nominations from across Canada that were assessed by a panel of judges. According to the Globe, the contest "recognizes talented Canadians who not only have great ideas, but also turn them into reality." Here's an excerpt: Another innovator who is taking on the traditional way of doing things is Ms. Kelley, ... Read more

Accel-Rx, the national health sciences accelerator, launches as a Centre of Excellence for Commercialization and Research (CECR)

MaRS Innovation among founding partner CECRs; Accel-Rx will provide funds to new biotechnology start-ups emerging within MI's portfolio VANCOUVER, BC (Aug. 25, 2014) –With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched. Media coverage of this announcement: CBC's Inside Politics blog, IT Business ... Read more

MaRS Innovation and St. Michael’s Hospital revitalizing commercialization process

For principal investigators, a key component in taking their research ideas from the bench to the market is knowing what commercialization resources exist and when to use them. Through the MaRS Innovation's Technology Transfer & Scouting division (MITTS), manager Sahail Shariff is connecting with principal investigators (PIs) at St. Michael's Hospital in Toronto on the front-line to better understand and advance their research. Of the 180 PIs at the hospital, the majority are clinician scientists who spend a portion of their time caring for patients. In collaboration ... Read more

Dr. Rafi Hofstein in Biotechnology Focus: What will it take to regain Canada’s biotechnology leadership?

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Dr. Raphael Hofstein. The article explores the role life sciences assets, financing and talented management--the three Ms--must play in revitalizing Canada's biotechnology sector: At the close of the 20th century, Canada was perceived as a key contributor to the success of the global biotech voyage. You know what happened next: the mechanisms to fund early ventures collapsed together with the collapse of the ... Read more
Page 4 of 12« First...23456...10...Last »